LungLifeAI Logo

Block Listing Six Monthly Return

May 15, 2024

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:LungLife AI, Inc.
Name of scheme:2010 Stock Incentive Plan2020 Stock Incentive Plan2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted:1,356,139 common shares of US $0.0001 each
Date of admission:15 November 2021
Period of return:From:15 November 2023To:15 May 2024
Balance of unallotted securities under scheme(s) from previous return:475,583201,374673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NILNILNIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):NILNILNIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:475,583201,374673,990
Total number of securities in issue at the end of the period30,658,603
Name of contact:David Anderson, Chief Financial Officer
Telephone number of contact:+44 (0)20 7933 8780 or

For further information please contact:

LungLife AI,
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO 
Investec Bank plc (Nominated Adviser & Broker)Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker)Tel: +44 (0) 20 3841 6202
Tom Nicholson / Cameron Duncan 
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or
Alice Woodings / Phillip MarriageMob: 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

Recent News

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.